EMA calls for high-quality observational research in context of COVID-19

By Published On: May 28th, 20201.2 min read

EMA calls for high-quality observational research in context of COVID-19

By Published On: May 28th, 20201.2 min read

The European Medicine Agency (EMA) encouraged collaboration between EU researchers on high-quality, multi-center observational studies of COVID-19 treatments and vaccines.

High-quality observational research of real world data collected during the pandemic can be an important complement to the results of randomized clinical trials in providing evidence on the safety and effectiveness of vaccines and treatments for COVID-19.

When planning observational studies, researchers should adhere to existing guidelines on the appropriate design and conduct of pharmacoepidemiological studies in order to generate reliable and reproduceable evidence.

A new COVID-19 response group, set up by the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP), is in place to simplify this collaboration.

For more details, please the official communication from EMA.

Meditrial can help – Contact us for immediate support

Meditrial has developed rapid workflows to conduct risk assessment, implement rescue plans and execute solutions for ongoing clinical trials:

Contact Meditrial for immediate assistance in Europe or the US.

Table of Contents

Latest Articles

This article provides general information and does not constitute regulatory, legal, clinical, or compliance advice. Requirements and appropriate processes may vary by study, product, jurisdiction, and organization. Medigen Suite functionality should be used in accordance with applicable regulations, study documentation, and internal procedures.

Go to Top